Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $16.00
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Zacks.com on MSN2d
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
It was a busy week for the biotech sector. While the fourth-quarter earnings season continues, other pipeline and regulatory ...
The Pharma Letter2d
Solid Biosciences surges on Duchenne therapy success
Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...
Solid Biosciences (SLDB) Gets a Buy from Barclays
In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target ...
JMP Securities Keeps Their Buy Rating on Solid Biosciences (SLDB)
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of ...
Stocktwits on MSN3d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?
Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Solid Biosciences stock soars on promising Duchenne therapy data
The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.